Navigation Links
Lilly Declares Third-Quarter Dividend
Date:6/20/2008

INDIANAPOLIS, June 20 /PRNewswire-FirstCall/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) today declared a dividend for the third quarter of 2008 of $0.47 a share on outstanding common stock. This is the same dividend as was paid in the first and second quarters and maintains the annual indicated dividend rate for 2008 of $1.88 per share.

The dividend is payable September 10, 2008, to shareholders of record at the close of business on August 15, 2008.

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at http://www.lilly.com. F-LLY

(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Statement of Eli Lilly and Company on Dr. David Egilman Settlement:
2. Robert J. Heine, M.D., Ph.D., F.R.C.P. to Join Lilly; Distinguished Diabetes Expert to Lead Diabetes/Endocrine Medical Division
3. Lauren Marangell, M.D. to Join Lilly; Internationally Recognized Expert in Depression Joins as Distinguished Lilly Scholar
4. Genentech/Roches Lucentis and Eli Lillys Ruboxistaurin Will Drive the Diabetic Retinopathy and Nephropathy Drug Markets
5. Lillys CEO Calls for Reform of Nations Drug Safety System
6. Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels
7. Lilly Grant to VA Will Enhance Services for Returning Combat Veterans
8. Lilly Delivers Strong Third-Quarter Results
9. Lilly and MacroGenics Announce Licensing and Collaboration Agreement
10. Eli Lilly and Company Aids California Recovery Effort
11. Eli Lilly and Company Announces 2007 Lilly Reintegration Awards Recipients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... insurance and financial consultation services to residents in the Sacramento/Folsom region, is initiating ... Chance treatment facility. , The Another Choice Another Chance treatment center in Sacramento ...
(Date:12/7/2016)... ... , ... AlignLife clinics nationwide are giving back to their communities by collecting ... bountiful gifts wrapped tightly under a Christmas Tree. AlignLife hopes to spread the ... , In exchange for generous donations, customers will receive a gift in return. ...
(Date:12/7/2016)... ... ... Sharon Kleyne, host of the nationally syndicated radio program, The Sharon Kleyne ... declared on her radio program in November 2016 the need to educate people about ... leaders in corporate America, they are trying to take advantage of successful algorithms and ...
(Date:12/7/2016)... , ... December 07, 2016 , ... Delete® - Tattoo ... Time For The Holiday Party Season. Save Up To 33% Off Botox® and Juvederm® ... is providing the Phoenix Valley with Delightful Deals on Botox® and Juvederm® ...
(Date:12/7/2016)... Studio City, CA (PRWEB) , ... December 07, 2016 , ... ... number during the holidays and winter seasons. One major study analyzing heart attacks ... January compared to August of a given year. We would all agree of course–no ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... -- Anaplastic Oligoastrocytoma - Pipeline Review, H2 2016 ... and Healthcare disease pipeline guide Anaplastic Oligoastrocytoma – ... the Anaplastic Oligoastrocytoma (Oncology) pipeline landscape. Anaplastic ... two types of cells in the brain, called ... form a mass. These brain cells are known ...
(Date:12/6/2016)... YORK , Dec. 6, 2016  Nearly 30 ... suffer from the epidemic of diabetes. 1 ... have persistently elevated glucose levels (hyperglycemia) and significant glucose variability. ... developing serious complications, including cardiovascular events. If left untreated, ... damage and eye disease or blindness. 3 ...
(Date:12/6/2016)... Dec. 6, 2016  Arcturus Therapeutics, Inc. ("Arcturus" ... announced today that it entered into collaboration with ... for the treatment of NASH and other gastrointestinal ... platform LUNAR™ and UNA Oligomer chemistry. The financial ... long-standing commitment to and expertise in GI disorders, ...
Breaking Medicine Technology: